(ALNY) Alnylam Pharmaceuticals - Ratings and Ratios
Therapeutics, RNA Interference, Amyloidosis, Porphyria, Hypercholesterolemia
ALNY EPS (Earnings per Share)
ALNY Revenue
Description: ALNY Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) is a biotechnology company that specializes in discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company has a robust pipeline of approved and investigational treatments for various rare and cardiovascular diseases, including hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia.
Key performance indicators (KPIs) for Alnylam Pharmaceuticals include revenue growth from its approved products, such as ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Leqvio. The companys ability to successfully advance its pipeline candidates, including vutrisiran, fitusiran, and cemdisiran, through clinical trials and regulatory approvals is also a crucial metric. Additionally, Alnylams collaborations with major pharmaceutical companies, such as Regeneron Pharmaceuticals, Roche Holding AG, and Sanofi S.A., can be seen as a validation of its technology and pipeline, and may contribute to future revenue growth.
From a financial perspective, Alnylams market capitalization stands at approximately $41 billion, indicating a significant market presence. The companys forward price-to-earnings ratio is around 2000, suggesting high growth expectations. Return on equity (ROE) is negative, which is not uncommon for biotech companies with significant R&D investments. To evaluate Alnylams performance, one should monitor its revenue growth, pipeline progress, and cash burn rate, as well as the companys ability to achieve key milestones and regulatory approvals.
To further assess Alnylams potential, one could analyze its research and development (R&D) expenses as a percentage of revenue, its cash and cash equivalents, and its total debt. Additionally, monitoring the companys guidance on future revenue and earnings, as well as its expectations for pipeline progress, can provide valuable insights into its growth prospects.
ALNY Stock Overview
| Market Cap in USD | 61,517m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2004-05-28 |
ALNY Stock Ratings
| Growth Rating | 78.2% |
| Fundamental | 34.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 43.7% |
| Analyst Rating | 4.0 of 5 |
ALNY Dividends
Currently no dividends paidALNY Growth Ratios
| Growth Correlation 3m | 91.4% |
| Growth Correlation 12m | 58.9% |
| Growth Correlation 5y | 71.5% |
| CAGR 5y | 30.15% |
| CAGR/Max DD 3y | 0.74 |
| CAGR/Mean DD 3y | 1.87 |
| Sharpe Ratio 12m | 0.16 |
| Alpha | 0.10 |
| Beta | 0.512 |
| Volatility | 36.39% |
| Current Volume | 1445.5k |
| Average Volume 20d | 1005.3k |
| Stop Loss | 437.8 (-3.1%) |
| Signal | -0.29 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-319.1m TTM) > 0 and > 6% of Revenue (6% = 147.7m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -8.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 95.16% (prev 90.33%; Δ 4.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.00 (>3.0%) and CFO -15.5m > Net Income -319.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (129.7m) change vs 12m ago 2.32% (target <= -2.0% for YES) |
| Gross Margin 83.64% (prev 87.00%; Δ -3.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.42% (prev 58.47%; Δ -1.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.49 (EBITDA TTM -170.9m / Interest Expense TTM 152.2m) >= 6 (WARN >= 3) |
Altman Z'' -4.09
| (A) 0.51 = (Total Current Assets 3.64b - Total Current Liabilities 1.30b) / Total Assets 4.57b |
| (B) -1.62 = Retained Earnings (Balance) -7.41b / Total Assets 4.57b |
| warn (B) unusual magnitude: -1.62 — check mapping/units |
| (C) -0.05 = EBIT TTM -227.4m / Avg Total Assets 4.29b |
| (D) -1.72 = Book Value of Equity -7.44b / Total Liabilities 4.32b |
| Total Rating: -4.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.06
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -0.07% = -0.04 |
| 3. FCF Margin -1.73% = -0.65 |
| 4. Debt/Equity 4.28 = -2.25 |
| 5. Debt/Ebitda -6.28 = -2.50 |
| 6. ROIC - WACC (= -27.74)% = -12.50 |
| 7. RoE -274.2% = -2.50 |
| 8. Rev. Trend 80.97% = 6.07 |
| 9. EPS Trend 58.41% = 2.92 |
What is the price of ALNY shares?
Over the past week, the price has changed by -4.33%, over one month by +0.96%, over three months by +49.37% and over the past year by +70.60%.
Is Alnylam Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALNY is around 521.18 USD . This means that ALNY is currently undervalued and has a potential upside of +15.37% (Margin of Safety).
Is ALNY a buy, sell or hold?
- Strong Buy: 12
- Buy: 12
- Hold: 7
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the ALNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 429.9 | -4.8% |
| Analysts Target Price | 429.9 | -4.8% |
| ValueRay Target Price | 577.6 | 27.9% |
Last update: 2025-09-12 04:30
ALNY Fundamental Data Overview
CCE Cash And Equivalents = 2.86b USD (Cash And Short Term Investments, last quarter)
P/E Forward = 52.6316
P/S = 24.9868
P/B = 245.4864
P/EG = -0.49
Beta = 0.32
Revenue TTM = 2.46b USD
EBIT TTM = -227.4m USD
EBITDA TTM = -170.9m USD
Long Term Debt = 1.03b USD (from longTermDebt, last quarter)
Short Term Debt = 46.1m USD (from shortTermDebt, last quarter)
Debt = 1.07b USD (Calculated: Short Term 46.1m + Long Term 1.03b)
Net Debt = 183.4m USD (from netDebt column, last quarter)
Enterprise Value = 59.73b USD (61.52b + Debt 1.07b - CCE 2.86b)
Interest Coverage Ratio = -1.49 (Ebit TTM -227.4m / Interest Expense TTM 152.2m)
FCF Yield = -0.07% (FCF TTM -42.6m / Enterprise Value 59.73b)
FCF Margin = -1.73% (FCF TTM -42.6m / Revenue TTM 2.46b)
Net Margin = -12.96% (Net Income TTM -319.1m / Revenue TTM 2.46b)
Gross Margin = 83.64% ((Revenue TTM 2.46b - Cost of Revenue TTM 402.7m) / Revenue TTM)
Tobins Q-Ratio = -8.03 (set to none) (Enterprise Value 59.73b / Book Value Of Equity -7.44b)
Interest Expense / Debt = 3.75% (Interest Expense 40.2m / Debt 1.07b)
Taxrate = 21.0% (US default)
NOPAT = -227.4m (EBIT -227.4m, no tax applied on loss)
Current Ratio = 2.80 (Total Current Assets 3.64b / Total Current Liabilities 1.30b)
Debt / Equity = 4.28 (Debt 1.07b / last Quarter total Stockholder Equity 250.6m)
Debt / EBITDA = -6.28 (Net Debt 183.4m / EBITDA -170.9m)
Debt / FCF = -25.19 (Debt 1.07b / FCF TTM -42.6m)
Total Stockholder Equity = 116.4m (last 4 quarters mean)
RoA = -6.99% (Net Income -319.1m, Total Assets 4.57b )
RoE = -274.2% (Net Income TTM -319.1m / Total Stockholder Equity 116.4m)
RoCE = -19.90% (Ebit -227.4m / (Equity 116.4m + L.T.Debt 1.03b))
RoIC = -19.92% (NOPAT -227.4m / Invested Capital 1.14b)
WACC = 7.82% (E(61.52b)/V(62.59b) * Re(7.90%)) + (D(1.07b)/V(62.59b) * Rd(3.75%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 76.93 | Cagr: 0.54%
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -42.6m)
EPS Correlation: 58.41 | EPS CAGR: 235.5% | SUE: 0.20 | # QB: 0
Revenue Correlation: 80.97 | Revenue CAGR: 47.78% | SUE: N/A | # QB: None
Additional Sources for ALNY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle